Market Newsdesk

NASHVILLE, Tenn., Dec. 03, 2020 (GLOBE NEWSWIRE) — Harrow Health, Inc. (NASDAQ: HROW) today announced that a study featuring its patented MKO Melt® formulation has been published in the American Association of Nurse Anesthetists (AANA) Journal. Each sublingually administered MKO Melt troche contains 3 mg of midazolam, 25 mg of ketamine, and 2 mg of ondansetron, and is available for institutional purchase through Harrow’s wholly-owned subsidiary, ImprimisRx®.  

ImprimisRx President John Saharek stated, “We are pleased that this study supports the consideration of non-opioid and needle-free MKO Melt as an alternative to traditional IV sedation, which often includes the opioid fentanyl. Further, for those patients with special challenges such as needle-phobia, who have difficult veins to access, or who simply prefer a sublingual alternative to IV administered sedation, the MKO Melt is an option for anesthesia professionals to consider. We look forward to continuing to support anesthesia providers and physicians who are seeking access to alternatives to opioids and needles for their patients.”

The MKO Melt, which has been administered in more than 250,000 cataract surgeries, is compounded in an FDA-registered and inspected outsourcing facility and is protected by patents issued in the United States and abroad.

Summary of the Study

The IRB-approved study compared the effectiveness and equivalency of a sublingual compounded non-opioid MKO Melt troche during monitored anesthesia sedation with traditional IV sedation for maintaining comfort in patients undergoing cataract surgery.   A total sample size of 107 patients were separated into two groups. One group received IV sedation consisting of fentanyl and midazolam (n=54) and the other group received sublingual MKO Melt (n=53).   Sixty percent of the patients in the study were having their first cataract surgery (n=64) and fifty-seven percent of the participants were female (n=61).   The primary endpoint of the study evaluated the comfort level between both groups for nausea, dizziness, pain, and sleepiness following the procedure. The authors of the study stated, “the results show comparable experiences for both groups with equivalency in patient comfort among both women and men.” Further, the authors concluded, “the findings support troche sedation as an effective and equivalent alternative to IV sedation in cataract surgery.”  

A link to the complete narrative of study, which discusses the benefits and limitations of the studied medications, is available here.  

The authors of the study reported no financial relationships with any commercial related entity connected to the study.

About Harrow Health

Harrow Health, Inc. (NASDAQ: HROW) owns a portfolio of ophthalmic pharmaceutical businesses, including ImprimisRx, the nation’s leading ophthalmology outsourcing facility and pharmaceutical compounding business. The company holds large equity positions in Eton Pharmaceuticals, Surface Ophthalmics, and Melt Pharmaceuticals. The Company also owns royalty rights in four clinical-stage drug candidates being developed by Surface and Melt. Supported by dedicated employees, Harrow intends to create, invest in and grow paradigm shifting healthcare businesses that put patients first. For more information about Harrow Health, please visit the Investor Relations section of the corporate website by clicking here.

No ImprimisRx compounded formulation is FDA-approved. All ImprimisRx formulations are customizable. Other than drugs compounded at a registered outsourcing facility, all ImprimisRx compounded formulations require a prescription for an individually identified patient consistent with federal and state laws.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward-looking statements.” Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to make commercially available our compounded formulations and technologies in a timely manner or at all; physician interest in prescribing our formulations; risks related to our compounding pharmacy operations; our ability to enter into other strategic alliances, including arrangements with pharmacies, physicians and healthcare organizations for the development and distribution of our formulations; our ability to obtain intellectual property protection for our assets; our ability to accurately estimate our expenses and cash burn, and raise additional funds when necessary; risks related to research and development activities; the projected size of the potential market for our technologies and formulations; unexpected new data, safety and technical issues; regulatory and market developments impacting compounding pharmacies, outsourcing facilities and the pharmaceutical industry; competition; and market conditions. These and additional risks and uncertainties are more fully described in Harrow Health’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Such documents may be read free of charge on the SEC’s web site at www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by law, Harrow Health undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

Investor Contact:
[email protected]

Source: Harrow Health, Inc. 

Dallas, Dec. 03, 2020 (GLOBE NEWSWIRE) — Thryv Holdings, Inc. (NASDAQ:THRY), the provider of Thryv^® software, the end-to-end client experience platform for small businesses, today announced that CEO and President Joe Walsh will participate in the UBS Global TMT Conference on Wednesday, December 9, 2020 at 10:15 a.m. ET. 

A live webcast will be available on Thryv’s Investor Relations page at investor.thryv.com. An archived replay will be made available for a limited time at the same location following the event. 

About Thryv Holdings, Inc.

The company owns the easy-to-use Thryv® end-to-end customer experience software built for small business that helps over 40,000 SaaS clients with the daily demands of running a business. With Thryv, they can get the job, manage the job and get credit. Thryv’s award-winning platform provides modernized business functions, allowing small-to-medium-sized businesses (SMB) to reach more customers, stay organized, get paid faster and generate reviews. These include building a digital customer database, automated marketing through email and text, updating business listings across the internet, scheduling online appointments, sending notifications and reminders, managing ratings and reviews, generating estimates and invoices and processing payments.

Thryv supports franchise operators and multi-location business owners with Hub by Thryv™, a software console that enables businesses managers to oversee their operations using the Thryv software.

Thryv also connects local businesses to consumer services through our search, display and social media management products, our print directories featuring The Real Yellow Pages® tagline, and our local search portals, which operate under the DexKnows.com®, Superpages.com® and Yellowpages.com URLs and reach some 35 million monthly visitors. For more information about the company, visit thryv.com.

Thryv delivers business services to more than 360,000 SMBs across America that enable them to compete and win in today’s economy.       

Learn more about Thryv on LinkedIn and Medium.

 

Media Contact:

Paige Blankenship

Thryv, Inc.

972.453.3012

[email protected]

 

Investor Contact:

Cameron Lessard 

Thryv, Inc.
    

214.773.7022 

[email protected]   

 

KJ Christopher

Thryv, Inc.

972.453.7068

[email protected]

 

###

Paige Blankenship
Thryv, Inc.
972.453.3012
[email protected]

TORONTO, Dec. 03, 2020 (GLOBE NEWSWIRE) — QuestCap Inc. (“QuestCap”) (CSE:QSC; FRA:34C1) is pleased to announce the inclusion of partner company Glenco Medical’s Standard for Safe Sport with the NBA’s Houston Rockets training camp for the 2020-2021 NBA season. This implementation includes the sale of 1,024 rapid antigen tests and 120 antibody tests to the Houston Rockets.

Houston Rocket players such as Danuel House Jr., David Nwaba, Ben McLemore, P.J. Tucker, and Chris Clemons are among the players that began limited workouts at Toyota Center as they begin preparing for the 2020-21 NBA season during the month of November. This week veteran players such as James Harden and Eric Gordon are reporting into The Toyota Center, as they spent their offseason time at homes outside of the Houston area.

“We are delighted to be the first NBA team to implement both the standard for safe sport and use of the testing modalities featured in the standard to increase the safety for our players during these challenging times to prepare for the new season” says Vice President of Houston Rockets’ Operations Mr. Keith Jones.

The Glenco protocols and procedures are currently in use by leaders of various industries including real estate, film production & entertainment, and the arts. According to statista.com the NBA generated combined revenues of around $8.76 billion U.S. dollars in 2018/19. This marks the highest figure to-date and is an increase of around $750 million U.S. dollars on the figure from the previous season. And while the tally of revenue loss is still being calculated for the year of the NBA bubble, revenues such as gate receipts, concessions, sponsorships and media broadcasting have been severely compromised or eliminated and the Houston Rockets organization is looking to shift that reality.

“The 2020-2021 NBA season is another special season, with a shorter schedule. We are preparing to bring fans back into the stands following QuestCap’s guidelines. The Toyota Center seats 18,300 in total, not including staff, security, coaches and trainers. It is our goal to seat 4,200 fans in the stands as permitted by the local governing bodies overseeing the health and safety of fellow Texans” says Mr. Jones.

The Standard for Safe Sport is a trademarked protocol developed originally by Glenco Medical, in which QuestCap owns a 30% equity interest, and is headed by renowned MLB physician, Dr. Glenn Copeland.

“We are very excited to be able to partner with the Houston Rockets and help them restore the spirit of competition and conditioning responsibly,” commented Doug Sommerville, QuestCap CEO. “We know the importance of safety in the professional sports realm and are proud to help empower a culture for both winning and safety with Glenco Medical’s protocols and QuestCap’s high-quality antibody and antigen testing solutions. We look forward to extending this to other teams that require our complete COVID-19 safety protocols.”

About Houston Rockets

The Houston Rockets are an American professional basketball team based in Houston. The Rockets compete in the National Basketball Association (NBA) as a member team of the league’s Western Conference Southwest Division. The team plays its home games at the Toyota Center, located in Downtown Houston. Throughout its history, Houston has won two NBA championships and four Western Conference titles. It was established in 1967 as the San Diego Rockets, an expansion team originally based in San Diego. In 1971, the Rockets relocated to Houston.

About QuestCap Inc.


QuestCap Inc.
 (NEO:QSC; OTC:COPRF; FRA:34C1)  seeks out disruptive technologies, ground-breaking innovations, and exclusive partnerships to help combat COVID-19 and generate remarkable risk-adjusted returns for investors. Specifically, QuestCap offers investors a diversified investment in the COVID-19 medical space across three areas; prevention, detection, and treatment.

QuestCap has a team of renowned global medical and business advisors that have developed a proprietary business strategy to capitalize on high-margin opportunities in the COVID-19 space. This panel includes prominent immunologist Dr. Lawrence Steinman and Dr. Glenn Copeland, who has 45 years of experience in orthopaedic treatment, foot and ankle care, and sports medicine.

QuestCap’s primary focus is the sale of COVID-19 IgG/IgM antibody tests authorized by FDA under an EUA for use by authorized laboratories. This is achieved largely through two acquisitions: 100% of Collection Sites, LLC and 28% of Colombian Sanaty IPS. Collection Sites is setting up a series of COVID-19 testing sites across the United States with appointments and payments will be handled through the online portal  www.testbeforeyougo.com. Sanaty is setting up a series of full-service medical clinics offering a complete COVID-19 testing solution.

For additional information, please contact:

Doug Sommerville, CEO
[email protected]

For investing enquires please contact:
Evan Veryard
[email protected]

For media enquires please contact:
Veronica Welch
[email protected]
+1-508-643-8000

Cautionary Note Regarding Forward-looking Information

This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements with respect to the implementation of the Standard for Safe Sport; the sale of COVID-19 testing; the potential rollout of the Standard for Safe Sport to other teams; the pursuit by QuestCap of investment opportunities; and the merits or potential returns of any such investments. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company, as the case may be, to be materially different from those expressed or implied by such forward-looking information. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAS REVIEWED OR ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

FREMONT, Calif., Dec. 03, 2020 (GLOBE NEWSWIRE) —  Aehr Test Systems (NASDAQ: AEHR), a worldwide supplier of semiconductor test and reliability qualification equipment, today announced it has received an initial $4.3 million order from a new customer that is a supplier of sensors to a major mobile device manufacturer consisting of a FOX-XP™ production test and burn-in system, a set of DiePak Carriers^®, and a FOX Automated DiePak loader / unloader for a new high-volume application for production test and burn-in of mobile sensors. 

Shipment of the initial test cell is expected during Aehr’s fiscal third quarter ending February 2021. Aehr expects follow-on capacity orders from this customer later in the current fiscal year for additional test systems, DiePaks, and DiePak loaders.

Gayn Erickson, President and CEO of Aehr Test Systems, commented, “We are incredibly proud to have been selected for this critical new application by a major mobile device supplier that will use these tools at a subcontractor in Asia. Aehr won this application due to our unique technical capabilities and cost effectiveness of our solution critical to this application, which will require 100% test, burn-in, traceability and validation of the devices. Our highly differentiated FOX solution achieved this test requirement and the customer’s low cost of test targets due to the significantly higher parallelism that can be attained on our FOX-XP systems and DiePaks.

“Our FOX systems provide more resources to the device under test interface boards than any other solution on the market. Our FOX-XP systems and DiePaks can deliver up to 2048 individual device power supplies with individual remote sense on every channel or 2048 digital pin driver/comparators or any combination of both as our universal channels allow software programmability on a pin-by-pin basis. This performance is unique in the industry and allows an unprecedented ability to configure the system to test thousands of devices without any resource sharing or hostage failures, which is essential in many applications where quality, reliability, safety, and security is critical.

“Sensors used in mobile devices such as smartphones, tablets, wearables such as watches and fitness bands, and audio devices have become pervasive. Initially, sensors on smartphones allowed basic functions we have all come to expect such as touchscreens, rotational sensors, and fingerprint sensors, but have gotten more complex with added capabilities such as 3D facial recognition and time of flight distance measurements. We will see the addition of health monitoring sensors, 3D measurement capability, and other advanced sensors in the future. As sensors become more pervasive and add critical new functionality to devices, it becomes more and more important that the data collected be accurate and reliable, which we believe will drive more and more requirements for our solutions for production test and burn-in of these sensors.”

Features in the FOX-XP and DiePak that are critical to this application and the selection of this test solution include:

• Individually programmable voltage and current sources per device to meet critical electrical test requirements and accuracy 
• Continuous per DUT monitoring and data logging of voltage, current, and sensors internal to the device throughout the test and burn-in duration 
• 100% validation and confirmation of test results and burn-in conditions without any hostage failures (where a device fails and impacts another device under test) 
• 100% traceability of devices from industry-standard JEDEC trays through DiePak loading to testing through DiePak unloading and sorting 
• Production proven test and burn-in system via Aehr’s FOX-XP multi-wafer and singulated die/module system and DiePak carriers that are capable of testing up to 1024 devices per DiePak
• Fully automated loading and unloading via a FOX DiePak loader/unloader provided by Aehr in a turnkey solution

The FOX-XP system, available with multiple WaferPak^TM Contactors (full wafer test) or multiple DiePak Carriers (singulated die/module test) configurations, is capable of functional test and burn-in/cycling of integrated devices such as 2D and 3D sensors, flash memories, Gallium Nitride (GaN), magnetic sensors, microcontrollers, optical modules, Silicon Carbide (SiC) and other leading-edge ICs in either wafer formfactor, before they are assembled into single or multi-die stacked packages, or in singulated die or module formfactor.

Aehr’s FOX-XP test and burn-in systems utilize Aehr proprietary DiePak Carriers to enable burn-in of singulated die and multi-die modules to screen for defects in both the die and the module assembly processes. The resulting known-good die, multi-die or stacked-die packaged parts can then be used for high reliability and quality applications such as 5G communications, enterprise solid-state drives, automotive devices, highly valuable mobile applications, and other mission-critical integrated circuits and sensors.

About Aehr Test Systems

Headquartered in Fremont, California, Aehr Test Systems is a worldwide provider of test systems for burning-in and testing logic, optical and memory integrated circuits and has installed over 2,500 systems worldwide. Increased quality and reliability needs of the Automotive and Mobility integrated circuit markets are driving additional test requirements, incremental capacity needs, and new opportunities for Aehr Test products in package, wafer level, and singulated die/module level test. Aehr Test has developed and introduced several innovative products, including the ABTS^TM and FOX-P^TM families of test and burn-in systems and FOX WaferPak^TM Aligner, FOX-XP WaferPak Contactor, FOX DiePak^® Carrier and FOX DiePak Loader. The ABTS system is used in production and qualification testing of packaged parts for both lower power and higher power logic devices as well as all common types of memory devices. The FOX-XP and FOX-NP systems are full wafer contact and singulated die/module test and burn-in systems used for burn-in and functional test of complex devices, such as leading-edge memories, digital signal processors, microprocessors, microcontrollers, systems-on-a-chip, and integrated optical devices. The FOX-CP system is a new low-cost single-wafer compact test and reliability verification solution for logic, memory and photonic devices and the newest addition to the FOX-P product family. The WaferPak contactor contains a unique full wafer probe card capable of testing wafers up to 300mm that enables IC manufacturers to perform test and burn-in of full wafers on Aehr Test FOX systems. The DiePak Carrier is a reusable, temporary package that enables IC manufacturers to perform cost-effective final test and burn-in of both bare die and modules. For more information, please visit Aehr Test Systems’ website at www.aehr.com.

Safe Harbor Statement

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally relate to future events or Aehr’s future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “going to,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” or “continue,” or the negative of these words or other similar terms or expressions that concern Aehr’s expectations, strategy, priorities, plans, or intentions. These statements are based on information available to Aehr as of the date hereof, are based on current expectations, forecasts and assumptions, and actual results could differ materially from those stated or implied due to risks and uncertainties. Forward-looking statements in this press release include, but are not limited to, statements regarding Aehr’s expectations, beliefs, intentions or strategies regarding its products and its business, including statements regarding future market opportunities and conditions; Aehr’s product capabilities; expected product shipment dates; customer orders, commitments or product uses; and Aehr’s collaboration with its customers. These forward-looking statements include risks and uncertainties such as, without limitation, customer demand and acceptance of Aehr’s products, the ability of new products to meet customer needs or perform as described, as well as general market conditions and Aehr’s ability to execute on its business strategy. The forward-looking statements contained in this press release are also subject to other risks and uncertainties, including those more fully described in Aehr’s recent 10-K, 10-Q and other reports from time to time filed with the Securities and Exchange Commission. Aehr disclaims any obligation to update information contained in any forward-looking statement to reflect events or circumstances occurring after the date of this press release.

Contacts: